Researchers hope the mixing-and-matching approach, known as a heterologous prime-boost, will incite a stronger immune response than receiving two doses of the same vaccine type.
Below are three examples of trials testing the approach:
- University of Oxford researchers are conducting a trial, partially funded by the U.K. government, in which 830 participants receive a dose of Pfizer’s COVID-19 vaccine followed by a dose of AstraZeneca’s shot, or vice versa. Pfizer’s vaccine uses an mRNA platform and AstraZeneca’s vaccine is based on an adenovirus.
- China’s National Institutes for Food and Drug Control is conducting trials that mix COVID-19 vaccine doses that are based on proteins, adenoviruses, RNA and coronaviruses that have been chemically inactivated, according to The New York Times.
- Russia’s Gamaleya Research Institute of Epidemiology and Microbiology is testing its vaccine, Sputnik V, along with AstraZeneca’s vaccine, both of which are based on adenoviruses.
More articles on pharmacy:
Pfizer, BioNTech to boost COVID-19 vaccine manufacturing to 2.5B doses
Eli Lilly, Vir & GSK say their COVID-19 antibody cocktail reduces viral load by 70%
Pfizer says its vaccine is 100% effective in preventing COVID-19 in adolescents
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
